What are the indications, dosing regimen, contraindications, adverse effects, and monitoring recommendations for flecainide (class IC antiarrhythmic)?

Flecainide Drug Information

Indications

Flecainide is indicated primarily for supraventricular tachyarrhythmias including atrial fibrillation (AF), atrial flutter, AV nodal reentrant tachycardia (AVNRT), and AV reentrant tachycardia (AVRT) in patients without structural heart disease. 1, 2

• For acute cardioversion of recent-onset AF: Intravenous flecainide (1.5-3.0 mg/kg over 10-20 minutes) or oral flecainide (200-300 mg single dose) is recommended, excluding patients with severe left ventricular hypertrophy, heart failure with reduced ejection fraction (HFrEF), or coronary artery disease 1

• For long-term rhythm control: Flecainide is recommended to prevent recurrence and progression of AF in patients without impaired left ventricular systolic function, severe left ventricular hypertrophy, or coronary artery disease 1

• For AVNRT: Flecainide at doses of 200-300 mg/day completely suppresses episodes in 65% of patients and demonstrates superior efficacy compared to verapamil (30% complete suppression vs 13% with verapamil) 1, 2

• For sustained ventricular tachycardia (VT): Flecainide may be used, though this indication requires in-hospital initiation with rhythm monitoring 3

Dosing Regimen

Supraventricular Arrhythmias (PSVT, PAF)

• Starting dose: 50 mg every 12 hours 3
• Titration: Increase by 50 mg twice daily every 4 days until efficacy is achieved 3
• Maximum dose: 300 mg/day 3
• Note: Steady-state plasma levels may not be achieved until 3-5 days of therapy at a given dose due to the long half-life (12-27 hours) 3

Sustained Ventricular Tachycardia

• Starting dose: 100 mg every 12 hours 3
• Titration: Increase by 50 mg twice daily every 4 days 3
• Usual effective dose: Most patients do not require more than 150 mg every 12 hours (300 mg/day) 3
• Maximum dose: 400 mg/day 3
• Critical: Must be initiated in-hospital with rhythm monitoring; loading doses are not recommended due to increased risk of proarrhythmic events and congestive heart failure 3

Pill-in-the-Pocket Approach

• Dose: 200-300 mg as a single oral dose for acute conversion of recent-onset AF 2
• Requirement: Safety must be established in a hospital setting before outpatient use 2, 4
• Monitoring: Initial trial should be performed in a monitored setting due to potential adverse reactions (3% incidence of significant adverse events) 4

Acute Cardioversion (IV)

• Dose: 1.5-3.0 mg/kg over 10-20 minutes 1

Special Populations

Severe renal impairment (creatinine clearance ≤35 mL/min/1.73 m²):

• Initial dose: 100 mg once daily (or 50 mg twice daily) 3
• Requires frequent plasma level monitoring 3

Moderate renal disease:

• Initial dose: 100 mg every 12 hours 3
• Plasma level monitoring useful during dosage adjustment 3

Concurrent amiodarone therapy:

• Reduce usual flecainide dose by 50% 3
• Plasma level monitoring strongly recommended 3

Pediatric dosing:

• Under 6 months: 50 mg/m² body surface area daily, divided into 2-3 doses 3
• Over 6 months: 100 mg/m² per day 3
• Maximum: 200 mg/m² per day (should not be exceeded) 3
• Must be supervised by a pediatric cardiologist skilled in arrhythmia management 3

Contraindications

Absolute Contraindications

Flecainide is absolutely contraindicated in patients with structural heart disease, coronary artery disease, or reduced left ventricular ejection fraction. 1, 2, 3

• Pre-existing second- or third-degree AV block, or right bundle branch block with left hemiblock (bifascicular block), unless a pacemaker is present 3

• Cardiogenic shock 3

• Known hypersensitivity to flecainide 3

• Prior myocardial infarction: Associated with increased mortality based on the CAST trial 2, 5

• Heart failure with reduced ejection fraction (HFrEF) 1

• Severe left ventricular hypertrophy 1

Relative Contraindications/Precautions

• Sinus node dysfunction or atrioventricular conduction disturbances unless risks for proarrhythmia and bradycardia have been carefully considered 1

• Prolonged QTc (>500 ms) 1

• Recent acute coronary syndrome 1

• Severe aortic stenosis (for vernakalant, but caution with all antiarrhythmics) 1

Adverse Effects

Cardiac Adverse Effects

• Hypotension 1
• Atrial flutter with high ventricular rate (1:1 conduction): This is a potentially dangerous complication requiring expertise in recognition and management 1, 5
• Proarrhythmia: Increased risk with higher plasma levels, especially >1 mcg/mL 3
• Conduction abnormalities: QRS prolongation (dose reduction or discontinuation required if QRS widens >25% from baseline) 5
• Negative inotropic effects: Use cautiously in patients with history of heart failure or myocardial dysfunction 3
• Symptomatic bradycardia 4
• Unexplained syncope 4

Non-Cardiac Adverse Effects

• Dizziness: Most frequent non-cardiac side effect 6
• Blurred vision and difficulty focusing 6
• Central nervous system effects: 5% discontinuation rate due to CNS side effects 1
• GI upset (less common) 6

Discontinuation Rates

• Overall discontinuation due to adverse effects: 5-20% in clinical trials 2
• Suboptimal clinical response: 7.6% discontinuation 1
• Non-cardiac side effects: 5% discontinuation 1

Serious Adverse Events with Pill-in-the-Pocket

• Incidence: 3% significant adverse events 4
• Events: Unexplained syncope, symptomatic bradycardia/hypotension, 1:1 atrial flutter 4
• All serious events occurred with: 300 mg flecainide or 600 mg propafenone 4
• Interventions required: Electrical cardioversion (11%), permanent pacemakers (2 patients), IV fluids and vasopressors 4

Monitoring Recommendations

Baseline Assessment

Before initiating flecainide, comprehensive cardiac assessment is essential to rule out structural heart disease. 5

• ECG parameters: PR interval, QRS duration, QTc interval, heart rate 7
• Echocardiography: To exclude structural heart disease, assess left ventricular function 5
• Renal function: Creatinine clearance for dose adjustment 3

During Therapy

Regular ECG monitoring is required, particularly when initiating treatment or adjusting dosage. 5

• QRS duration monitoring: Critical safety parameter

  • Dose reduction or discontinuation if QRS widens >25% from baseline 5
  • Monitor for QRS widening >150% of baseline 7

• Plasma level monitoring:

  • Therapeutic range: 0.2-1.0 mcg/mL (most successfully treated patients) 3
  • Increased adverse effects: Probability increases with trough levels >1 mcg/mL 3
  • Mandatory monitoring: Severe renal failure, severe hepatic disease, concurrent amiodarone therapy, heart failure, moderate renal disease 3
  • Timing: Trough levels (less than 1 hour pre-dose) at presumed steady state (after at least 5 doses) 3

Pediatric Monitoring

• Plasma trough levels and 12-lead ECG: Obtain at presumed steady state after initiation or dose change 3
• First year: 12-lead ECG and plasma trough level at each clinical follow-up visit 3
• Therapeutic level in children: 200-500 ng/mL (up to 800 ng/mL may be required in some cases) 3
• Warning: Small dose changes may lead to disproportionate increases in plasma levels 3

Concomitant Medications

• AV nodal blocking agents: Often required when using flecainide to prevent rapid ventricular conduction if atrial flutter occurs 5
• Beta-blockers: Frequently combined to enhance efficacy and reduce risk of 1:1 AV conduction 1, 2
• Amiodarone: Reduce flecainide dose by 50% and monitor closely 3
• Donepezil (Aricept): Additive effects on cardiac conduction increase risk of symptomatic bradycardia, heart block, or syncope; consider alternative antiarrhythmics or minimize donepezil dose 7

Clinical Pearls and Pitfalls

Common Pitfalls to Avoid

• Failure to exclude structural heart disease: This is the most critical error, as flecainide is contraindicated in these patients and associated with increased mortality 2, 5

• Inadequate monitoring for QRS widening: QRS prolongation is a key indicator of potential proarrhythmia risk 5

• Using flecainide without AV nodal blockade: Risk of 1:1 atrial flutter with rapid ventricular response 1

• Initiating pill-in-the-pocket without in-hospital trial: 3% risk of significant adverse events requiring urgent intervention 4

• Rapid dose escalation: Increases risk of proarrhythmic events and heart failure, especially in sustained VT 3

Special Considerations

• Specialist oversight recommended: Flecainide requires careful patient selection and specialized cardiac evaluation, best accomplished by cardiologists or electrophysiologists 5

• Drug interactions: Well documented and manageable, but require attention (particularly amiodarone, AV nodal blockers) 3

• Renal dysfunction: Requires dose adjustment and frequent monitoring due to markedly slower elimination 3

• Pregnancy and children: Limited but available data; requires specialist supervision 3, 8